I couldn't negotiate the editing language to make some minor changes to the list.
JAV's US Dyloject is not intranasal, this is injectible diclofenac. JAV also has a P3 drug that IS intranasal: Ketamine (Ereska) that is due for an NDA in 2009.
Criteria 1. Unparterned 2. Not enough cash to bring the product to market 3. Lets say at least started Phase 3 trials 4. Its on a product basis so if company a has 2 unparterned Phase 3 products and not enough cash then an entry for each would be appropriate
Stock Product Stage Comments ----- --------------- --------------------- ----------------------------- NTII Viprinex Phase 3 Interim analysis January '09. Stroke Drug, high chance of failure. BPAX Libigel Phase 3 ~2010 Submit Adequate Safety? EPIX Vasovist PDUFA 12/30/08 FDA initially rejected saying 2 more studies needed. Allowed reread company states results very positive. Looking to sell outright on approval. RPRX Proellex Phase 3 Uterine fibroids CHTP Droxidopa Pivotal Phase III Orthostatic hypotension. Results expected 02/09 JAV Dyloject Phase III Approved in UK. Post operative Pain (injectable) JAV Ketamine Phase III Acute moderate-to-severe pain (intranasal) GNVC TNFerade Pivotal Phase III Pancreatic cancer
----- Updating the list 1. Reply to this post copying all the text 2. Changed the "EDITS:" to account for changes, e.g. Edits: Added Viprinex 3. Please put [ pre ] at the begining of the table without surrounding spaces are "pre". 4. Please put [ /pre ] at the end of the table without surrounding spaces around "pre".